150 related articles for article (PubMed ID: 16208470)
1. Role of tumour-associated N-glycolylated variant of GM3 ganglioside in cancer progression: effect over CD4 expression on T cells.
de Leòn J; Fernández A; Mesa C; Clavel M; Fernández LE
Cancer Immunol Immunother; 2006 Apr; 55(4):443-50. PubMed ID: 16208470
[TBL] [Abstract][Full Text] [Related]
2. Differential influence of the tumour-specific non-human sialic acid containing GM3 ganglioside on CD4+CD25- effector and naturally occurring CD4+CD25+ regulatory T cells function.
de León J; Fernández A; Clavell M; Labrada M; Bebelagua Y; Mesa C; Fernández LE
Int Immunol; 2008 Apr; 20(4):591-600. PubMed ID: 18310617
[TBL] [Abstract][Full Text] [Related]
3. Cytofluorimetric evaluation of N-glycolylated GM3 ganglioside expression on murine leukocytes.
Miranda A; de León J; Roque-Navarro L; Fernández LE
Immunol Lett; 2011 Jun; 137(1-2):38-45. PubMed ID: 21324343
[TBL] [Abstract][Full Text] [Related]
4. Direct validation of NGcGM3 ganglioside as a new target for cancer immunotherapy.
Labrada M; Clavell M; Bebelagua Y; León Jd; Alonso DF; Gabri MR; Veloso RC; Vérez V; Fernández LE
Expert Opin Biol Ther; 2010 Feb; 10(2):153-62. PubMed ID: 20088712
[TBL] [Abstract][Full Text] [Related]
5. Anti-ganglioside antibody-induced tumor cell death by loss of membrane integrity.
Roque-Navarro L; Chakrabandhu K; de León J; Rodríguez S; Toledo C; Carr A; de Acosta CM; Hueber AO; Pérez R
Mol Cancer Ther; 2008 Jul; 7(7):2033-41. PubMed ID: 18645013
[TBL] [Abstract][Full Text] [Related]
6. A cytotoxic humanized anti-ganglioside antibody produced in a murine cell line defective of N-glycolylated-glycoconjugates.
Fernández-Marrero Y; Roque-Navarro L; Hernández T; Dorvignit D; Molina-Pérez M; González A; Sosa K; López-Requena A; Pérez R; de Acosta CM
Immunobiology; 2011 Dec; 216(12):1239-47. PubMed ID: 21802167
[TBL] [Abstract][Full Text] [Related]
7. Ganglioside control over IL-4 priming and cytokine production in activated T cells.
Chen XP; Ding X; Daynes RA
Cytokine; 2000 Jul; 12(7):972-85. PubMed ID: 10880242
[TBL] [Abstract][Full Text] [Related]
8. CAR T cells targeting the ganglioside NGcGM3 control ovarian tumors in the absence of toxicity against healthy tissues.
Cribioli E; Giordano Attianese GMP; Coukos G; Irving M
Front Immunol; 2022; 13():951143. PubMed ID: 35990626
[TBL] [Abstract][Full Text] [Related]
9. NGcGM3 ganglioside: a privileged target for cancer vaccines.
Fernandez LE; Gabri MR; Guthmann MD; Gomez RE; Gold S; Fainboim L; Gomez DE; Alonso DF
Clin Dev Immunol; 2010; 2010():814397. PubMed ID: 21048926
[TBL] [Abstract][Full Text] [Related]
10. Cancer vaccines: an update with special focus on ganglioside antigens.
Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
[TBL] [Abstract][Full Text] [Related]
11. Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challenge.
Mazorra Z; Mesa C; Fernández A; Fernández LE
Cancer Immunol Immunother; 2008 Dec; 57(12):1771-80. PubMed ID: 18351335
[TBL] [Abstract][Full Text] [Related]
12. Monosialoganglioside GM3 induces CD4 internalization in human peripheral blood T lymphocytes.
Sorice M; Pavan A; Misasi R; Sansolini T; Garofalo T; Lenti L; Pontieri GM; Frati L; Torrisi MR
Scand J Immunol; 1995 Feb; 41(2):148-56. PubMed ID: 7863261
[TBL] [Abstract][Full Text] [Related]
13. A novel mechanism of CD4 down-modulation induced by monosialoganglioside GM3. Involvement of serine phosphorylation and protein kinase c delta translocation.
Garofalo T; Sorice M; Misasi R; Cinque B; Giammatteo M; Pontieri GM; Cifone MG; Pavan A
J Biol Chem; 1998 Dec; 273(52):35153-60. PubMed ID: 9857052
[TBL] [Abstract][Full Text] [Related]
14. Effects of gangliosides GM3 and De-N-acetyl GM3 on epidermal growth factor receptor kinase activity and cell growth.
Song WX; Vacca MF; Welti R; Rintoul DA
J Biol Chem; 1991 Jun; 266(16):10174-81. PubMed ID: 1645342
[TBL] [Abstract][Full Text] [Related]
15. Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand.
Park JE; Wu DY; Prendes M; Lu SX; Ragupathi G; Schrantz N; Chapman PB
Immunology; 2008 Jan; 123(1):145-55. PubMed ID: 18154620
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of tumor cell vaccine after incorporating monophosphoryl lipid A (MPL) in tumor cell membranes containing tumor-associated ganglioside.
Ravindranath MH; Brazeau SM; Morton DL
Experientia; 1994 Jul; 50(7):648-53. PubMed ID: 8033972
[TBL] [Abstract][Full Text] [Related]
17. p56lck, LFA-1 and PI3K but not SHP-2 interact with GM1- or GM3-enriched microdomains in a CD4-p56lck association-dependent manner.
Barbat C; Trucy M; Sorice M; Garofalo T; Manganelli V; Fischer A; Mazerolles F
Biochem J; 2007 Mar; 402(3):471-81. PubMed ID: 17123354
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effects of the GM3(Neu5Gc) ganglioside-specific humanized antibody 14F7hT against Cmah-transfected cancer cells.
Dorvignit D; Boligan KF; Relova-Hernández E; Clavell M; López A; Labrada M; Simon HU; López-Requena A; Mesa C; von Gunten S
Sci Rep; 2019 Jul; 9(1):9921. PubMed ID: 31289278
[TBL] [Abstract][Full Text] [Related]
19. A purified GM3 ganglioside conjugated vaccine induces specific, adjuvant-dependent and non-transient antitumour activity against B16 mouse melanoma in vitro and in vivo.
Carr A; Mazorra Z; Alonso DF; Mesa C; Valiente O; Gomez DE; Perez R; Fernandez LE
Melanoma Res; 2001 Jun; 11(3):219-27. PubMed ID: 11468510
[TBL] [Abstract][Full Text] [Related]
20. Amplified ELISA to detect autoantibodies to N-glycolyl-GM3 ganglioside.
Iznaga N; Carr A; Fernández LE; Solozabal J; Núñez G; Perdomo Y; Morales A
J Clin Lab Immunol; 1996; 48(2):75-85. PubMed ID: 16296265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
